Skip to content

GastroIntestinal Carcinoids

1. Introduction to Gastrointestinal Carcinoids

  • Historical Background
    • First descriptions and early discoveries
    • Development of nomenclature and the term "carcinoid"
  • Biology of the Neuroendocrine System
    • Overview of the neuroendocrine system and its components
    • The role of enteroendocrine cells in the GI tract

2. Classification and Nomenclature

  • Types of Carcinoid Tumors
    • Well-differentiated NETs vs. poorly differentiated NETs
  • Common Terminology
    • Historical terms and current accepted nomenclature (e.g., GEP-NETs)
  • World Health Organization (WHO) Classification
    • Changes and updates in classification over the years

3. Epidemiology and Incidence

  • Incidence Rates
    • Prevalence of GI carcinoids in the general population
  • Risk Factors
    • Genetic predispositions and environmental exposures
    • Familial syndromes associated with GI carcinoids

4. Clinical Presentation

  • Symptoms of GI Carcinoids
    • Carcinoid syndrome and other common presentations
  • Diagnostic Challenges
    • Difficulty in diagnosing due to vague symptoms and anatomical locations

5. Diagnostic Evaluation

  • Laboratory Tests
    • Role of 24-hour urine 5-HIAA and serum chromogranin A (CgA) in diagnosis
  • Radiographic Evaluation
    • Use of CT, MRI, Octreoscan, and endoscopic techniques
  • Differential Diagnosis
    • Other conditions that may present similarly

6. Tumor Staging and Grading

  • Staging Systems
    • TNM staging systems by AJCC and ENETS
  • Tumor Grading
    • Proliferative index markers: Mitotic rate and Ki67 labeling

7. Gastrointestinal Carcinoids by Location

  • Gastric Neuroendocrine Tumors
    • Types I-IV, their characteristics, and treatment options
  • Small Intestinal Neuroendocrine Tumors
    • Presentation, diagnosis, and treatment strategies
  • Colon and Rectal Neuroendocrine Tumors
    • Clinical features and treatment approaches
  • Appendiceal Neuroendocrine Tumors
    • Incidence, diagnosis, and management

8. Management of Metastatic Disease

  • Somatostatin Analogues
    • Role in symptomatic management and progression control
  • Surgical Options
    • Resection of metastatic and primary tumors, hepatic metastasis management
  • Systemic Chemotherapy
    • Current options and emerging targeted therapies

9. Perioperative and Surgical Considerations

  • Avoidance of Carcinoid Crisis
    • Preoperative and intraoperative management strategies
  • Evaluation for Carcinoid Heart Disease
    • Importance of screening and management during surgery

10. Prognosis and Follow-Up

  • Survival Rates
    • Factors influencing prognosis based on tumor type and treatment
  • Surveillance Strategies
    • Post-treatment monitoring and follow-up protocols

11. Emerging Research and Future Directions

  • Unresolved Issues in Carcinoid Pathobiology
    • Areas of ongoing research and future potential treatments

image.png

MCQ: Management of Type I Gastric Carcinoids

Answer: B - Endoscopic Mucosal Resection (EMR)

Explanation:

  • Type I gastric carcinoids are associated with chronic hypergastrinemia, usually due to chronic atrophic gastritis. These tumors are generally small, multiple, and well-differentiated, with a low risk of malignancy.
  • For lesions measuring 1-2 cm in size, as in this case (1.5 cm), Endoscopic Mucosal Resection (EMR) is the recommended approach. This minimally invasive procedure allows for the effective removal of the lesions while preserving gastric anatomy.

Key Points On Management Strategy of Gastric Carcinoids:

  • Type I: with chronic hypergastrinemia, usually due to chronic atrophic gastritis
    • Size < 1 cm: Observation is recommended due to the low risk of malignancy.
    • Size > 1 cm: Endoscopic Mucosal Resection (EMR) is recommended for effective management.
    • Surgical Intervention: Considered if the tumor is >2 cm, if there are positive nodes, or if there are >6 lesions present.
  • Type II: Linked with Zollinger-Ellison syndrome; typically involves multiple, small, and benign lesions.
    • Treat Gastrinoma
  • Type III: Not associated with hypergastrinemia; worst prognosis among gastric carcinoids; often large and may present with carcinoid syndrome.
  • Type IV: Non-ECL tumor; associated with parietal cell hyperplasia; typically more locally invasive with metastatic potential.
    • Type III and IV Management: Surgery with lymphadenectomy is the standard treatment approach due to the higher risk of malignancy and metastasis.

WHO 2019 Classification of Neuroendocrine Tumors (NETs)

Terminology Differentiation Grade Ki67 (MIB1) Index
NET G1 Well-differentiated Low < 3%
NET G2 Well-differentiated Intermediate 3-20%
NET G3 Well-differentiated High > 20%
NEC Small Cell (SCNEC) Poorly differentiated High > 20%
NEC Large Cell (LCNEC) Poorly differentiated High > 20%
MiNEN Well or poorly differentiated Variable Variable

MiNENs (Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms)

  • Definition:
    • MiNENs are neoplasms with both a neuroendocrine component and a non-neuroendocrine component.
  • Composition:
    • Each component must comprise at least 30% of all neoplastic cells.
  • Non-Neuroendocrine Component:
    • The non-neuroendocrine component does not necessarily have to be an adenocarcinoma, and one or both components may not be carcinomas.
  • Grading:
    • Both components should be graded, and even small cell neuroendocrine carcinoma (SCNEC) should be graded if it is less than 30%.
  • Qualification Criteria:
    • The presence of scattered neuroendocrine cells (<30%) in adenocarcinomas does not qualify for a diagnosis of MiNEN.
  • Diagnosis:
    • MiNENs should be diagnosed only on resection specimens, as the identification of these components requires thorough histopathological evaluation.

MCQ: Most Common Neuroendocrine Tumor of the Pancreas

Answer: A - Non-functional NET

Explanation:

  • Most Common Pancreatic Neuroendocrine Tumor (NET):
    • The most common neuroendocrine tumor of the pancreas is non-functional NET. These tumors do not secrete hormones in clinically significant amounts, and they often present later in the disease course, typically due to mass effect or metastatic disease.

Key Points Summary:

  • Most Common (MC) NET: Non-functional NET is the most common type of pancreatic neuroendocrine tumor.
  • MC Functional Tumor: Gastrinoma > Insulioma
    • The statement that either gastrinoma or insulinoma could be the most common functional tumor requires clarification. While both are common functional pancreatic NETs, insulinoma is generally considered the most common functional pancreatic NET overall, especially in sporadic cases. Gastrinoma is more common in the context of Multiple Endocrine Neoplasia type 1 (MEN1).
  • MC Functional Pancreatic Islet Cell Tumor in MEN1: Gastrinoma is the most common functional pancreatic islet cell tumor in patients with MEN1.
  • MC pNET in MEN1: The most common pancreatic NET in MEN1 patients is non-functional, but among the functional types, gastrinoma is the most prevalent.

MCQ: Acid Hypersecretion with Hypergastrinemia

Answer: D - Hepatic failure

Explanation:

  • Acid Hypersecretion and Hypergastrinemia:
    • Acid hypersecretion associated with hypergastrinemia can occur in various conditions where there is an increased production of gastrin, often in response to an underlying stimulus such as impaired gastric emptying, renal dysfunction, or bacterial colonization.
    • Conditions associated with acid hypersecretion and hypergastrinemia include:
      • Helicobacter pylori (H. pylori) infection: Leads to chronic gastritis, which can stimulate excess gastrin production.
      • Renal failure: Leads to reduced clearance of gastrin, resulting in hypergastrinemia.
      • Peptic ulcer disease: Hypergastrinemia can be a secondary response to increased acid production or in conditions such as Zollinger-Ellison syndrome.
      • Retained antrum syndrome: Occurs when the antrum is inadvertently left behind after gastric surgery, continuing to produce gastrin in response to food.
  • Condition not associated with acid hypersecretion and hypergastrinemia:
    • Hepatic failure (Answer D): This condition typically does not lead to acid hypersecretion or hypergastrinemia, as the liver’s primary role is in metabolizing and clearing hormones rather than directly influencing acid secretion.

MCQ: Diagnosis of Zollinger-Ellison Syndrome

Answer: C - Serum gastrin is more elevated in gastrinoma associated with MEN 1 syndrome compared to sporadic gastrinoma

Explanation:

  • Point C (False Statement):
    • The assertion that "serum gastrin is more elevated in gastrinoma associated with MEN 1 syndrome compared to sporadic gastrinoma" is false. In fact, serum gastrin levels can be significantly elevated in both conditions, but they are often higher in sporadic gastrinomas compared to those associated with MEN1. This discrepancy is due to the multifocal nature and typically smaller size of gastrinomas in MEN1, which often results in a less pronounced elevation of serum gastrin compared to the larger, solitary tumors seen in sporadic cases.
  • Zollinger-Ellison Syndrome (ZES):
    • Overview:
      • Zollinger-Ellison Syndrome is a rare condition characterized by the formation of one or more gastrin-secreting tumors, known as gastrinomas, typically located in the pancreas or duodenum.
      • The excessive secretion of gastrin leads to increased gastric acid production, which can result in peptic ulcers, gastroesophageal reflux disease (GERD), and chronic diarrhea.
    • Diagnostic Criteria:
      • Fasting Serum Gastrin: A fasting serum gastrin level >1000 pg/mL is strongly suggestive and often considered diagnostic of ZES, particularly when accompanied by a low gastric pH (<2).
        • 1-3% pt’s can have Normal Serum gastrin
        • Good screening test for ZES.
      • Secretin Stimulation Test: In cases where fasting gastrin levels are not diagnostic, a secretin stimulation test can be performed, where an exaggerated increase in gastrin levels following secretin administration supports the diagnosis.
      • Serum Chromogranin A & Synaptophysin: These markers are typically elevated in neuroendocrine tumors, including gastrinomas, and can be useful in supporting the diagnosis.
    • Clinical Features:
      • Gastric Acid Hypersecretion: Leads to severe peptic ulcer disease, which may be refractory to standard treatment.
      • Diarrhea: Results from the excessive acid secretion leading to mucosal injury and impaired digestion.
      • GERD: Is a common manifestation due to the high acid load.
    • Association with MEN1:
      • MEN1 (Multiple Endocrine Neoplasia type 1): About 25-30% of patients with ZES have MEN1, which is characterized by the presence of multiple endocrine tumors, including gastrinomas, parathyroid adenomas, and pituitary tumors.
      • In MEN1-associated ZES, gastrinomas are often smaller, multiple, and located in the duodenum, and they may present with lower serum gastrin levels compared to sporadic cases where the tumors are often solitary and larger.

Diagnosis Based on Gastrin Levels and Secretin Stimulation

35-year-old male presented with chief complaints of abdominal pain for 3 months. Previous history of gastric surgery done for peptic ulcer disease. Fasting serum gastrin is 250 pg/ml along with gastric pH <2. On secretin stimulation test, serum gastrin value was found to be 110 pg/ml. What is the most probable diagnosis?

  • A: Gastrinoma
  • B: H. pylori infection
  • C: Retained antrum syndrome
  • D: Short gut syndrome

Answer: C - Retained antrum syndrome

Explanation:

  • Context:
    • Retained Antrum Syndrome can occur after partial gastrectomy where a portion of the antrum is inadvertently left behind. The retained antral tissue continues to produce gastrin in response to food, leading to hypergastrinemia and gastric acid secretion.
    • In this case, the fasting serum gastrin level of 250 pg/mL with a gastric pH <2 is suggestive of a condition causing hypergastrinemia with acid hypersecretion. The secretin stimulation test shows a decrease in serum gastrin to 110 pg/mL, which is typical for retained antrum syndrome rather than gastrinoma.
  • Secretin Stimulation Test in Gastrinoma Diagnosis:
    • Gastrinoma (Zollinger-Ellison Syndrome) is characterized by an increase in serum gastrin levels following secretin administration, which is paradoxical because secretin normally inhibits gastrin release.
    • Diagnostic Criterion:
      • A rise in baseline gastrin levels by >120 pg/mL after secretin administration is considered diagnostic for gastrinoma. Some sources may use different cut-offs, with an increase >200-300 pg/mL being strongly indicative of gastrinoma.
  • Cut-Off Values and Interpretation:
    • Baseline Serum Gastrin:
      • In gastrinoma, the fasting serum gastrin level is often significantly elevated, frequently >1000 pg/mL, but levels can also be lower, especially in the early stages or in cases associated with MEN1.
    • Secretin Stimulation Test:
      • The secretin test is particularly useful when fasting serum gastrin levels are elevated but not diagnostic. A rise of >120 pg/mL or more, or achieving levels >200-300 pg/mL after secretin administration, strongly suggests gastrinoma.
      • not necessary to stop PPI’s
      • In retained antrum syndrome, serum gastrin levels typically decrease or remain unchanged after secretin administration, as seen in this case.
  • Key Takeaway:
    • In the presented scenario, the decrease in serum gastrin levels following secretin stimulation suggests a non-gastrinoma cause of hypergastrinemia, such as retained antrum syndrome. However, had the gastrin level increased significantly (>120 to >300 pg/mL), gastrinoma would be the most likely diagnosis.

MCQ: Preoperative Localization of Suspected Gastrinoma

Answer: D - Selective arteriography

Explanation:

  • Selective Arteriography:
    • Role and Usage:
      • Selective arteriography is primarily an intraoperative localization technique rather than a preoperative one. It involves injecting contrast into specific arteries and then monitoring for changes in gastrin levels to identify the exact location of the gastrinoma. This technique is particularly useful during surgery when other localization methods have been inconclusive.
    • Intraoperative Use: It helps surgeons pinpoint the location of small or ectopic gastrinomas that may not have been identified preoperatively using imaging techniques. However, due to the advancement of more precise imaging techniques, the use of selective arteriography has become less common in favor of less invasive methods.
  • Affinity for Receptors of Ga-DOTATATE and Ga-DOTANOC:
    • Ga-DOTATATE:
      • Ga-DOTATATE has a high affinity for somatostatin receptor subtype 2 (SSTR2), which is highly expressed in well-differentiated neuroendocrine tumors (NETs), including gastrinomas. It is particularly effective for imaging well-differentiated NETs.
    • Ga-DOTANOC:
      • Ga-DOTANOC has a broader receptor affinity, binding not only to SSTR2 but also to somatostatin receptor subtypes 3 (SSTR3) and 5 (SSTR5). This makes it useful for detecting a wider range of NETs, including some that may not express SSTR2 as strongly.
    • Use in Poorly Differentiated NEC:
      • Poorly differentiated neuroendocrine carcinomas (NEC) often have a lower expression of somatostatin receptors, especially SSTR2. As a result, the efficacy of Ga-DOTATATE and Ga-DOTANOC for imaging these tumors is reduced. In poorly differentiated NECs, FDG-PET scans may be more appropriate due to their higher metabolic activity rather than receptor-based imaging.
  • Where the Other Investigations Are Used:
    • PET Scan:
      • Positron Emission Tomography (PET) scans, especially when combined with tracers like 68Ga-DOTATATE, are highly effective for preoperative localization of gastrinomas. They are used to identify primary tumors as well as metastatic lesions, especially in well-differentiated NETs.
    • Ga-DOTATATE and Ga-DOTANOC:
      • Both Ga-DOTATATE and Ga-DOTANOC are used in somatostatin receptor imaging to localize NETs, including gastrinomas. They are commonly employed in the preoperative setting to detect both primary and metastatic disease. Due to their high affinity for somatostatin receptors, they are particularly useful in well-differentiated tumors.
      • Ga-DOTATATE is often preferred due to its strong affinity for SSTR2, but Ga-DOTANOC offers broader receptor binding, making it versatile for a wider range of NETs.
    • CT/MRI:
      • CT and MRI are highly effective for identifying hypervascular lesions associated with gastrinomas. These imaging modalities are particularly useful for visualizing the primary tumor and assessing the extent of metastatic disease.
      • Hypervascularity on imaging is a characteristic feature of gastrinomas, helping in distinguishing them from other lesions.
    • Endoscopic Ultrasound (EUS):
      • EUS is considered the best modality for detecting small lesions, especially those located in the pancreas or duodenum. Its high-resolution capability allows for detailed imaging of the gastrointestinal wall and surrounding structures, making it particularly useful for detecting small gastrinomas that might be missed on other imaging studies.
    • Ga-DOTATATE PET vs. Octreotide Scintigraphy:
      • Ga-DOTATATE PET is superior to Octreotide scintigraphy for the detection of neuroendocrine tumors, including gastrinomas. Ga-DOTATATE PET offers better spatial resolution and sensitivity, leading to more accurate localization of both primary and metastatic disease.
      • Octreotide scintigraphy (SRS) has been widely used but is gradually being replaced by Ga-DOTATATE PET due to the latter's improved diagnostic accuracy.

MCQ: Management and Outcomes in Gastrinoma

Answer: D - All patients with negative localization but with biochemical evidence should be offered surgery

Explanation:

  • Point D (False Statement):
    • The statement that "all patients with negative localization but with biochemical evidence should be offered surgery" is false. Surgical intervention should be carefully considered in cases with negative localization, especially in the context of sporadic versus familial (MEN1-associated) gastrinomas.

Management of Gastrinoma with Negative Localization:

  • Sporadic Gastrinoma:
    • For patients with sporadic gastrinoma, if localization studies are negative, the general approach is to still consider surgery. This is because sporadic gastrinomas are often solitary and have a higher likelihood of being cured with surgical resection once localized, even if it requires a more thorough or extensive search during the operation. The rationale behind offering surgery even with negative localization stems from the possibility of eventual identification and resection during exploratory surgery.
  • Familial Gastrinoma (MEN1):
    • In contrast, for familial gastrinoma associated with MEN1 (Multiple Endocrine Neoplasia type 1), the approach is generally more conservative when localization studies are negative. Observation is often preferred over surgery due to the multifocal nature of these tumors and the higher likelihood of multiple small, hard-to-localize lesions. Surgical exploration without clear localization is less favored in MEN1 due to the potential for recurrent disease and the morbidity associated with extensive surgery in these patients.
      • Image negative in MEN 1 - Observation alone
      • Extensive disease in MEN 1 - Observation alone
  • Key Points on Gastrinoma Management:
    • R1 Resection Survival: Patients with an R1 resection (microscopic residual disease) can have a relatively high 10-year survival rate, often around 85%, due to the slow-growing nature of well-differentiated gastrinomas.
    • Liver Metastasis: 70-80% of patients with gastrinoma present with liver metastasis at the time of diagnosis, highlighting the aggressive potential of this disease.
    • Negative Localization Tests: 20-30% of patients may have negative localization studies despite biochemical evidence of gastrinoma, complicating the decision-making process for surgical intervention.

Determinants of Long-Term Survival in Gastrinoma

Answer: A - Lymph node metastasis

Explanation:

  • Most Important Determinant:
    • Liver Metastasis (B) is the most significant determinant of long-term survival in patients with gastrinoma. The presence of liver metastasis is associated with a markedly worse prognosis compared to those without liver involvement.
  • Tumor Size:
    • Tumor Size is another important factor. Gastrinomas that are >3 cm in size have approximately a 60% chance of metastasis, which directly impacts survival. Larger tumors are more likely to metastasize and thus have a poorer prognosis.
  • Lymph Node Metastasis:
    • Lymph Node Metastasis (A): Unlike liver metastasis, lymph node involvement by itself does not significantly affect long-term survival. While lymph node metastasis indicates a more advanced disease, it is not as critical as liver metastasis in determining overall survival outcomes.
  • Location of Tumor:
    • Location of the Tumor: The prognosis of gastrinoma can also depend on its location. Duodenal gastrinomas generally have a better prognosis than those located in the pancreas or those that are combined (involving both duodenal and pancreatic sites). The location influences both the likelihood of complete resection and the biological behavior of the tumor.

Key Points Summary:

  • Liver Metastasis (B): Most important determinant of long-term survival; significantly worsens prognosis.
  • Tumor Size: Tumors >3 cm have a higher risk of metastasis, influencing survival negatively.
  • Lymph Node Metastasis (A): Does not significantly impact long-term survival; less critical than liver metastasis.
  • Tumor Location: Duodenal gastrinomas have a better prognosis than pancreatic or combined gastrinomas.